Abstract
Treatment resistant depression is commonly defined as a depressive disorder that does not remit after two therapeutic trials of antidepressant treatment. However, different factors can contribute to treatment resistance, and not all cases that qualify as “treatment resistant” require advanced therapies. Similar to many other kinds of health conditions, some strategies for overcoming treatment resistance in depression can be effectively implemented from within primary care, whereas others are more likely to involve referring to a specialist or sub-specialist. Regardless of whether they are prescribing or administering advanced treatments in their own clinics, primary care providers should understand what these treatments entail and what their own roles should be in collaborating with other providers to ensure that their patients get the best health outcomes possible.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am. 1996;19:179–200.
Voineskos D, Daskalakis JZ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–34.
Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17:111–26.
McIntyre RS, Filteau M, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
Rickels K. Buspirone in clinical practice. J Clin Psychiatry. 1990;51(Suppl):51–4.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed; 2010.
Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019;2019:CD010557.
Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psych. 2020;11:595584.
Rissardo JP, Caprara ALF. Buspirone-associated movement disorders: a literature review. Prague Med Rep. 2020;121:5–24.
Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord. 2017;217:266–80.
Post RM. The new news about lithium: an underutilized treatment in the United States. Neuropsychopharmacology. 2018;43:1174–9.
MacLeod-Glover N, Chuang R. Chronic lithium toxicity: considerations and systems analysis. Can Fam Physician. 2020;66:258–61.
Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387:1240–50.
Viron M, Baggett T, Hill M, Freudenreich O. Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. Am J Med. 2012;125:223–330.
American Psychiatric Association. The American Psychiatric Association practice guidelines for the treatment of patients with schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021.
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2010.
Bahji A, Mesbah-Oskui L. Comparative efficacy of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–23.
Andrew BN, Guan NC, Jaafar N. The use of methylphenidate for physical and psychological symptoms in cancer patients: a review. Curr Drug Targets. 2018;19:877–87.
Anderson SL, Vande Griend JP. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm. 2014;71:394–402.
Preda A, Shapiro BB. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020;19:1529–38.
Carbon M, Hsieh C, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264-78.
Shriqui CL, Bradwejn J, Jones BD. Tardive dyskinesia: legal and preventive aspects. Can J Psychiatr. 1990;35:576–80.
Cantù F, Ciappolino V, Enrico P, et al. Augmentation with atypical antipsychotics for treatment-resistant depression. J Affect Disord. 2021;280(Pt A):45–53.
Fornaro M, Fusco A, Anastasia A, et al. Brexpiprazole for treatment-resistant major depressive disorder. Expert Opin Pharmacother. 2019;20:1925–33.
Milev RV, Giacobbe P, Kennedy SH, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments. Can J Psychiatr. 2016;61:561–75.
Hermida AP, Mohsin M, Marques Pinheiro AP, et al. Cardiovascular side effects of electroconvulsive therapy and their management. J ECT. 2021; https://doi.org/10.1097/YCT.0000000000000802.
Bottomley JM, LeReun C, Diamantopoulos A, et al. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: a systematic review and meta-analysis. Compr Psychiatry. 2019;98:152156.
Krauss JK, Lipsman N, Azizi T, et al. Technology of deep brain stimulation: current status and future directions. Nat Rev Neurol. 2021;17:75–87.
Kisely S, Li A, Warren N, Siskind D. A systematic review and meta-analysis of deep brain stimulation for depression. Depress Anxiety. 2018;35:468–80.
Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176:401–9.
Marcantoni WS, Akoumba BS, Wassef M, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009-January 2019. J Affect Disord. 2020;277:831–41.
DeWilde KE, Levitch CF, Murrough JW, et al. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015;1345:47–58.
Swainson J, Thomas RK, Archer S, et al. Esketamine for treatment resistant depression. Expert Rev Neurother. 2019;19:899–911.
Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat. 2017;74:399–405.
Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205–15.
Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428–38.
Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiat. 2018;75:139–48.
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2019;
Li JM, Zhang Y, Su W, et al. Cognitive behavioral therapy for treatment-resistant depression: a systematic review and meta-analysis. Psychiatry Res. 2018;268:243–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kroll, D.S. (2022). Treatment Resistance and Advanced Therapies. In: Caring for Patients with Depression in Primary Care. Springer, Cham. https://doi.org/10.1007/978-3-031-08495-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-031-08495-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-08494-2
Online ISBN: 978-3-031-08495-9
eBook Packages: MedicineMedicine (R0)
